$CKX
CKX Lands Inc

2024 Q2 Form 10-Q Financial Statement

#000143774924016203 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $1.027M $141.9K
YoY Change 177.4% -14.43%
Cost Of Revenue $17.71K $14.35K
YoY Change 33.96% 40.69%
Gross Profit $1.010M $127.5K
YoY Change 182.71% -18.04%
Gross Profit Margin 98.28% 89.88%
Selling, General & Admin $503.1K $563.0K
YoY Change 98.09% -13.02%
% of Gross Profit 49.83% 441.6%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.065K $1.066K
YoY Change 0.0% 0.09%
% of Gross Profit 0.11% 0.84%
Operating Expenses $504.2K $564.1K
YoY Change 97.67% -12.99%
Operating Profit $646.1K -$436.6K
YoY Change 532.83% 27.36%
Interest Expense $50.88K $50.22K
YoY Change 43.16% 93.45%
% of Operating Profit 7.87%
Other Income/Expense, Net $13.75K
YoY Change
Pretax Income $710.8K -$386.4K
YoY Change 416.4% 21.95%
Income Tax $145.5K $14.94K
% Of Pretax Income 20.47%
Net Earnings $565.3K -$401.3K
YoY Change 447.6% 68.88%
Net Earnings / Revenue 55.02% -282.92%
Basic Earnings Per Share $0.28 -$0.20
Diluted Earnings Per Share $0.27 -$0.20
COMMON SHARES
Basic Shares Outstanding 2.027M 1.991M
Diluted Shares Outstanding 2.063M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.393M $8.751M
YoY Change 12.01% 6.65%
Cash & Equivalents $7.867M $7.243M
Short-Term Investments $1.527M $1.507M
Other Short-Term Assets $125.8K $136.3K
YoY Change 4.29% 4.04%
Inventory
Prepaid Expenses
Receivables $136.6K $95.09K
Other Receivables $32.61K $0.00
Total Short-Term Assets $9.688M $8.982M
YoY Change 12.79% 6.76%
LONG-TERM ASSETS
Property, Plant & Equipment $9.093M $9.094M
YoY Change -0.05% -0.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $168.7K $314.2K
YoY Change -51.08% -17.16%
Total Long-Term Assets $9.262M $9.408M
YoY Change -1.92% -0.7%
TOTAL ASSETS
Total Short-Term Assets $9.688M $8.982M
Total Long-Term Assets $9.262M $9.408M
Total Assets $18.95M $18.39M
YoY Change 5.09% 2.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $219.8K $63.74K
YoY Change 875.89% 106.01%
Accrued Expenses
YoY Change
Deferred Revenue $95.11K $153.2K
YoY Change 1.67% 3.06%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $466.3K $368.4K
YoY Change 301.73% 105.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $466.3K $368.4K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $466.3K $368.4K
YoY Change 301.73% 105.07%
SHAREHOLDERS EQUITY
Retained Earnings $15.54M $14.97M
YoY Change 2.92% -0.14%
Common Stock $59.34K $59.34K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.48M $18.02M
YoY Change
Total Liabilities & Shareholders Equity $18.95M $18.39M
YoY Change 5.09% 2.8%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $565.3K -$401.3K
YoY Change 447.6% 68.88%
Depreciation, Depletion And Amortization $1.065K $1.066K
YoY Change 0.0% 0.09%
Cash From Operating Activities $691.8K -$337.8K
YoY Change 255.51% 273.75%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $140.6K $34.49K
YoY Change -86.01% -77.01%
Cash From Investing Activities $140.6K $34.49K
YoY Change -85.96% -74.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -208.9K
YoY Change
NET CHANGE
Cash From Operating Activities 691.8K -$337.8K
Cash From Investing Activities 140.6K $34.49K
Cash From Financing Activities -208.9K
Net Change In Cash 623.5K -$303.4K
YoY Change -47.86% -818.11%
FREE CASH FLOW
Cash From Operating Activities $691.8K -$337.8K
Capital Expenditures $0.00 $0.00
Free Cash Flow $691.8K -$337.8K
YoY Change 261.79% 213.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
95085 usd
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000352955
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
CY2023Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0 usd
CY2024Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0 usd
CY2023Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2024Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
104741 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
212279 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9388882 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9095403 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
329121 usd
CY2023Q4 us-gaap Assets
Assets
18813406 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
63744 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
159159 usd
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
151404 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
151404 usd
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
153246 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
184785 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
368394 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
495348 usd
CY2024Q1 us-gaap Liabilities
Liabilities
368394 usd
CY2023Q4 us-gaap Liabilities
Liabilities
495348 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2014283
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2014283
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1991337
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1991337
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
59335 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
59335 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3255881 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3150376 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
22496
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
22496
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
263748 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
263748 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
14970766 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15372095 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18022234 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18318058 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18390628 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18813406 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
563040 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
647303 usd
CY2024Q1 us-gaap Depreciation
Depreciation
1066 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1065 usd
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
578455 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
508571 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-436606 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-342809 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
50218 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
25958 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-386388 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-316851 usd
CY2024Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
14941 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-79212 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14941 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79212 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-401329 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-237639 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1991337
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1974427
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18318058 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105505 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-401329 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18022234 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17420414 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-237639 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17709245 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-401329 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-237639 usd
CY2024Q1 us-gaap Depreciation
Depreciation
1066 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1065 usd
CY2024Q1 us-gaap Depletion
Depletion
20 usd
CY2023Q1 us-gaap Depletion
Depletion
0 usd
CY2024Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
14941 usd
CY2023Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-79212 usd
CY2024Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
-0 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
149992 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
105505 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
526470 usd
CY2024Q1 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
-68913 usd
CY2023Q1 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
63544 usd
CY2024Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-126954 usd
CY2023Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-87539 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-337838 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90391 usd
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1500000 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
-0 usd
CY2024Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1534485 usd
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 usd
CY2024Q1 ckx Payments Of Reforesting Timber Costs
PaymentsOfReforestingTimberCosts
-0 usd
CY2023Q1 ckx Payments Of Reforesting Timber Costs
PaymentsOfReforestingTimberCosts
17358 usd
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
149992 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34485 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
132634 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-303353 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42243 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7546689 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7148207 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7243336 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7190450 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Concentration of Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company maintains its cash balances in nine financial institutions. At times, cash balances may exceed the Federal Deposit Insurance Corporation’s insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes the Company is not exposed to any significant credit risk on its cash balances.</p>
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36551
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
310794
CY2023Q1 us-gaap Depletion
Depletion
0 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9187180 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9187200 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
92863 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
91797 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9094317 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9095403 usd
CY2024Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
149992 usd
CY2024Q1 us-gaap Depreciation
Depreciation
1066 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1065 usd
CY2024Q1 us-gaap Depletion
Depletion
20 usd
CY2023Q4 ckx Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedNumber
71788
CY2024Q1 ckx Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedNumber
123549
CY2024Q1 ckx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue
3374002 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
118121 usd
CY2024Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
22946
CY2024Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
71788

Files In Submission

Name View Source Status
ckx-20240331_def.xml Edgar Link unprocessable
0001437749-24-016203-index-headers.html Edgar Link pending
0001437749-24-016203-index.html Edgar Link pending
0001437749-24-016203.txt Edgar Link pending
0001437749-24-016203-xbrl.zip Edgar Link pending
ckx-20240331.xsd Edgar Link pending
ckx-20240331_cal.xml Edgar Link unprocessable
ckx20240331_10q.htm Edgar Link pending
ex_669347.htm Edgar Link pending
ex_669348.htm Edgar Link pending
ex_669353.htm Edgar Link pending
ex_669354.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ckx-20240331_lab.xml Edgar Link unprocessable
ckx-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ckx20240331_10q_htm.xml Edgar Link completed